Source comparison
BPC-157 20s Age-Specific Protocol: Research Compound Comparison
BPC-157 FAK-paxillin pathway activation, VEGF upregulation, angiogenesis 250–500 mcg daily ~4–6 hours (requires daily dosing) 4–8 weeks on, equal off Best for soft tissue injury, tendon repair, gut healing. Systemic benefits beyond localised pain relief TB-500
This comparison does not assign a generated winner or score.
- BPC-157
- FAK-paxillin pathway activation, VEGF upregulation, angiogenesis
- 250–500 mcg daily
- ~4–6 hours (requires daily dosing)
- 4–8 weeks on, equal off
- Best for soft tissue injury, tendon repair, gut healing. Systemic benefits beyond localised pain relief
- TB-500 (Thymosin Beta-4)
- Actin upregulation, cell migration, anti-inflammatory
- 2–5 mg twice weekly
- 7–10 days
- 4–6 weeks on, 4 weeks off
- Stronger anti-inflammatory effect, longer half-life. Preferred for muscle tears and systemic inflammation
- MK 677
- Growth hormone secretagogue, IGF-1 elevation
- 10–25 mg daily
- 24 hours
- 3–6 months on, 1 month off
- Indirect tissue repair through GH/IGF-1. Synergises with BPC-157 but targets different pathways
- Dihexa
- BDNF upregulation, neuroplasticity
- 1–5 mg daily
- Unknown (experimental)
- Unclear. Limited human data
- Cognitive enhancement focus, not tissue repair. Minimal overlap with BPC-157 use cases
- Collagen Peptides (oral)
- Provides glycine, proline, hydroxyproline for collagen synthesis
- 10–20 g daily
- N/A (amino acids)
- Continuous use
- Substrate provision only. Does not upregulate signalling pathways like BPC-157
- BPC-157 stands out for its direct modulation of growth factor pathways rather than substrate provision or indirect hormone elevation. TB-500 is the closest functional analogue but works through actin regulation rather than VEGF. Combining BPC-157 with collagen peptides or MK 677 addresses both signalling and substrate availability.